RAPT Therapeutics (RAPT) Competitors $1.06 -0.05 (-4.50%) Closing price 04:00 PM EasternExtended Trading$1.06 +0.00 (+0.47%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RAPT vs. CDMO, QURE, ABCL, CMRX, PRAX, BCAX, LENZ, PRTA, AVBP, and ORGOShould you be buying RAPT Therapeutics stock or one of its competitors? The main competitors of RAPT Therapeutics include Avid Bioservices (CDMO), uniQure (QURE), AbCellera Biologics (ABCL), Chimerix (CMRX), Praxis Precision Medicines (PRAX), Bicara Therapeutics (BCAX), LENZ Therapeutics (LENZ), Prothena (PRTA), ArriVent BioPharma (AVBP), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. RAPT Therapeutics vs. Avid Bioservices uniQure AbCellera Biologics Chimerix Praxis Precision Medicines Bicara Therapeutics LENZ Therapeutics Prothena ArriVent BioPharma Organogenesis Avid Bioservices (NASDAQ:CDMO) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, community ranking, institutional ownership, media sentiment, dividends, valuation and profitability. Is CDMO or RAPT more profitable? RAPT Therapeutics has a net margin of 0.00% compared to Avid Bioservices' net margin of -101.07%. Avid Bioservices' return on equity of -33.18% beat RAPT Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avid Bioservices-101.07% -33.18% -8.45% RAPT Therapeutics N/A -89.10%-76.13% Which has more volatility and risk, CDMO or RAPT? Avid Bioservices has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of -0.29, indicating that its share price is 129% less volatile than the S&P 500. Which has preferable earnings & valuation, CDMO or RAPT? RAPT Therapeutics has lower revenue, but higher earnings than Avid Bioservices. Avid Bioservices is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvid Bioservices$139.91M5.71-$140.75M-$2.39-5.23RAPT Therapeutics$1.53M91.89-$116.80M-$3.11-0.34 Does the MarketBeat Community favor CDMO or RAPT? Avid Bioservices received 279 more outperform votes than RAPT Therapeutics when rated by MarketBeat users. Likewise, 65.95% of users gave Avid Bioservices an outperform vote while only 63.19% of users gave RAPT Therapeutics an outperform vote. CompanyUnderperformOutperformAvid BioservicesOutperform Votes37065.95% Underperform Votes19134.05% RAPT TherapeuticsOutperform Votes9163.19% Underperform Votes5336.81% Do analysts rate CDMO or RAPT? Avid Bioservices presently has a consensus target price of $12.25, suggesting a potential downside of 1.96%. RAPT Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 275.59%. Given RAPT Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe RAPT Therapeutics is more favorable than Avid Bioservices.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avid Bioservices 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00RAPT Therapeutics 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11 Do institutionals and insiders believe in CDMO or RAPT? 97.2% of Avid Bioservices shares are owned by institutional investors. Comparatively, 99.1% of RAPT Therapeutics shares are owned by institutional investors. 3.1% of Avid Bioservices shares are owned by company insiders. Comparatively, 6.6% of RAPT Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to CDMO or RAPT? In the previous week, Avid Bioservices' average media sentiment score of 0.00 equaled RAPT Therapeutics'average media sentiment score. Company Overall Sentiment Avid Bioservices Neutral RAPT Therapeutics Neutral SummaryRAPT Therapeutics beats Avid Bioservices on 9 of the 16 factors compared between the two stocks. Remove Ads Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPT vs. The Competition Export to ExcelMetricRAPT TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$140.59M$6.38B$5.30B$7.10BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-0.386.7722.8717.44Price / Sales91.89187.34356.4784.46Price / CashN/A65.6738.1634.64Price / Book0.255.596.233.78Net Income-$116.80M$141.89M$3.20B$247.10M7 Day Performance-12.70%-11.74%-8.27%-7.70%1 Month Performance-3.18%-14.80%-3.22%-10.48%1 Year Performance-86.70%-18.57%3.38%-7.81% RAPT Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPTRAPT Therapeutics3.3044 of 5 stars$1.06-4.5%$4.00+277.4%-86.7%$139.93M$1.53M-0.3880CDMOAvid Bioservices0.9437 of 5 stars$12.50+0.1%$12.25-2.0%+89.6%$799.18M$139.91M-5.23320High Trading VolumeQUREuniQure2.3435 of 5 stars$14.77+7.8%$38.89+163.3%+83.3%$798.72M$27.12M-2.98500Analyst ForecastAnalyst RevisionNews CoverageGap DownABCLAbCellera Biologics2.0157 of 5 stars$2.59+6.1%$7.00+170.3%-52.3%$771.79M$28.83M-4.25500News CoverageGap DownCMRXChimerix3.3598 of 5 stars$8.50flat$8.53+0.4%+720.2%$764.46M$159,000.00-9.0490Positive NewsPRAXPraxis Precision Medicines1.931 of 5 stars$37.71+1.6%$123.80+228.3%-37.2%$760.35M$8.55M-3.66110News CoverageGap DownBCAXBicara TherapeuticsN/A$13.87+4.7%$36.50+163.2%N/A$754.59MN/A0.0032Analyst RevisionLENZLENZ Therapeutics2.0551 of 5 stars$26.66+0.6%$41.67+56.3%+8.4%$733.18MN/A-5.59110PRTAProthena2.7469 of 5 stars$13.35+2.9%$55.00+312.1%-53.3%$718.38M$135.16M-5.80130Gap DownAVBPArriVent BioPharma1.1839 of 5 stars$20.21+3.5%$39.00+93.0%-6.5%$687.46MN/A-7.8640ORGOOrganogenesis3.4509 of 5 stars$5.42+11.1%$5.50+1.5%+46.9%$687.41M$482.04M-90.33950 Remove Ads Related Companies and Tools Related Companies Avid Bioservices Competitors uniQure Competitors AbCellera Biologics Competitors Chimerix Competitors Praxis Precision Medicines Competitors Bicara Therapeutics Competitors LENZ Therapeutics Competitors Prothena Competitors ArriVent BioPharma Competitors Organogenesis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPT) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | SponsoredControversial opinion: Volume isn't enough.Don’t be fooled by volume alone — it's just one piece of the trading puzzle. High demand doesn’t matter if sup...MillPub | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RAPT Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RAPT Stock Free RAPT Stock Alerts